Predicting later differential DMD patient quality of life of distinct corticosteroid regimens via serum proteome and steroid hormone profiling

Award Details:

Carleton University received a $657,945 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2025, with a completion date of May 31, 2028. The award supports research titled "Predicting Later Differential DMD Patient Quality of Life of Distinct Corticosteroid Regimens via Serum Proteome and Steroid Hormone Profiling," conducted at the university's Ottawa, Ontario facility.

Research Scope and Products:

This three-year research initiative aims to advance clinical outcomes for Duchenne muscular dystrophy (DMD) patients by developing predictive models for quality of life outcomes associated with different corticosteroid treatment regimens. The project delivers advanced biomedical research services focused on proteome analysis and steroid hormone profiling to identify biomarkers that differentiate patient responses to corticosteroid therapies. The research supports the DHA's mission to transform healthcare for military service members and the American public through innovative medical solutions, with deliverables anticipated to inform evidence-based clinical practice guidelines and therapeutic decision-making for DMD management.